# EDGAR Filing Document

**Accession Number:** 0001716166
**File Stem:** 0002074003-26-000008
**Filing Date:** 2026-4
**Character Count:** 8761
**Document Hash:** 0633cc75977cd7dd1030a2234584056b
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0002074003-26-000008.hdr.sgml**: 20260402

**ACCESSION NUMBER**: 0002074003-26-000008

**CONFORMED SUBMISSION TYPE**: 4

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20260331

**FILED AS OF DATE**: 20260402

**DATE AS OF CHANGE**: 20260402

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Skaff Michael C
- **CENTRAL INDEX KEY:** 0002074003

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39796
- **FILM NUMBER:** 26836346

**MAIL ADDRESS:**
- **STREET 1:** TWO TOWNE SQUARE
- **STREET 2:** STE. 810
- **CITY:** SOUTHFIELD
- **STATE:** MI
- **ZIP:** 48076
**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** V-Co Investors 3 LLC
- **CENTRAL INDEX KEY:** 0002114460

**ORGANIZATION NAME:**
- **STATE OF INCORPORATION:** WY
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39796
- **FILM NUMBER:** 26836345

**BUSINESS ADDRESS:**
- **STREET 1:** 18000 MACK AVENUE
- **CITY:** GROSSE POINTE
- **STATE:** MI
- **ZIP:** 48234
- **BUSINESS PHONE:** 248-723-6650

**MAIL ADDRESS:**
- **STREET 1:** 18000 MACK AVENUE
- **CITY:** GROSSE POINTE
- **STATE:** MI
- **ZIP:** 48234
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Vivos Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001716166
- **STANDARD INDUSTRIAL CLASSIFICATION:** SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 813224056
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 7921 SOUTHPARK PLAZA,
- **STREET 2:** SUITE 210
- **CITY:** LITTLETON
- **STATE:** CO
- **ZIP:** 80120
- **BUSINESS PHONE:** (866)908-4867

**MAIL ADDRESS:**
- **STREET 1:** 7921 SOUTHPARK PLAZA,
- **STREET 2:** SUITE 210
- **CITY:** LITTLETON
- **STATE:** CO
- **ZIP:** 80120

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Vivos BioTechnologies, Inc.
- **DATE OF NAME CHANGE:** 20170901

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 4

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

[ ] Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Skaff Michael C<br><sub>(Last) (First) (Middle)</sub><br>18000 MACK AVE<br><sub>(Street)</sub><br>GROSSE POINTE, MI 48230<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2026-03-31 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director [X] 10% Owner<br>[ ] Officer (give title below) [ ] Other (specify below)<br>_ _ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>Vivos Therapeutics, Inc. [ VVOS ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[ ] Form filed by One Reporting Person<br>[X] Form filed by More than One Reporting Person |

---

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>V-Co Investors 3 LLC<br><sub>(Last) (First) (Middle)</sub><br>18000 MACK AVE<br><sub>(Street)</sub><br>GROSSE POINTE, MI 48230<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2026-03-31 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director [X] 10% Owner<br>[ ] Officer (give title below) [ ] Other (specify below)<br>_ _ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>Vivos Therapeutics, Inc. [ VVOS ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[ ] Form filed by One Reporting Person<br>[X] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | 3. Transaction Code (V) | 3. Transaction Code (V) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | Code | V | Amount | (A) or (D) | Price | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| Common Stock | 2026-03-31 |  | P |  | 1044777<sup>(1)</sup> | A | $1.34 | 1044777 | I | By V-CO Investors 3 LLC<sup>(2)</sup> |
| Common Stock | 2026-03-31 |  | P |  | 308848 | A | $1.34 | 1353625 | I | By V-CO Investors 3 LLC<sup>(2)</sup> |

---

## Table II - Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | 4. Transaction Code (V) | 4. Transaction Code (V) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 6. Date Exercisable and Expiration Date | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Underlying Securities | 7. Title and Amount of Underlying Securities | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| Pre-Funded Warrant | $0.0001 | 2026-03-31 |  | P |  | 429957 |  | 2026-03-31 | <sup>(3)</sup> | Common Stock | 429957 | $1.34 | 429957 | I | By V-CO Investors 3 LLC<sup>(2)</sup> |
| Series A Common Stock Warrant | $1.09 | 2026-03-31 |  | P |  | 1783582 |  | 2026-03-31 | 2028-03-31 | Common Stock | 1783582 | $1.34 | 1783582 | I | By V-CO Investors 3 LLC<sup>(2)</sup> |
| Series B Common Stock Warrant | $1.09 | 2026-03-31 |  | P |  | 1783582 |  | 2026-03-31 | 2031-03-31 | Common Stock | 1783582 | $1.34 | 1783582 | I | By V-Co Investors 3 LLC<sup>(2)</sup> |

---

### Footnotes:

(1) On March 31, 2026, V-Co Investors 3, LLC  converted a bridge promissory note in the amount of $1,400,000 entered into between the reporting person and the Issuer into shares of the Issuer's common stock, based on $1.09 per share of Common Stock plus $0.25 per share in accordance with the Nasdaq minimum price rules.

(2) Michael C. Skaff serves as Managing Director of SP Manager LLC, the Manager of V-Co Investors 3 LLC. Michael C. Skaff and SP Manager LLC disclaim beneficial ownership of these securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that such persons are the beneficial owners of such securities for purposes of Section 16 or for any other purpose.

(3) The Pre-Funded Warrant has a term ending on the complete exercise of the Pre-Funded Warrant.

**Signature:** /s/ Michael C. Skaff, as Managing Director SP Manager LLC, Manager of V-Co Investors 3 LLC  
**Date:** 2026-04-02

**Signature:** /s/ Michael C. Skaff, Individual  
**Date:** 2026-04-02

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**